Company intelligence / Profile preview

Chengdu New Radiomedicine Technology

Chengdu, Sichuan, Chinaen.nrtmedtech.com ↗

Ownership: Private
Employees: ~260
Development stage: Commercial

Overview

NRT’s lead product, TareSphere™ Yttrium‑90 Carbon Microspheres, is in Phase 3 trials for unresectable hepatocellular carcinoma and Phase 1/2 trials for pancreatic cancer in China. The company has also received IND approvals from the US FDA for its FAP-targeted diagnostic and therapeutic radiopharmaceuticals, demonstrating international R&D capabilities.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalSmall moleculeRadionuclide drug conjugateRecombinant polypeptide
Industry: Biotech

Drug pipeline

6 assets

NRT6008

5 more assets in the full pipeline.

Request access →

Partnerships

Eckert & Ziegler (partnered to build Yttrium‑90 chloride solution production line)BTG Group (investor)

Beyond the preview

Go deeper on Chengdu New Radiomedicine Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu New Radiomedicine Technology.

Explore the full profile